Loading
Immunotherapy and Immune Responses / Monoclonal and Polyclonal Antibodies Research · Journal article
Discover Oncology · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic review proposing antibody-lectin chimeras (AbLecs) as a novel immunotherapeutic strategy to overcome tumor glycan-mediated immune evasion. The concept is supported by preclinical data in humanized mouse models showing superiority of HER2-directed AbLecs over trastuzumab in reducing tumor burden and metastases, but no clinical trial or human efficacy data are provided. The work frames a hypothesis and engineering approach rather than establishing clinical evidence.
Journal article.
HER2-directed AbLecs outperform trastuzumab in reducing tumor burden and lung metastases in humanized Siglec mouse models AbLecs achieve dual recognition of protein antigens and hypersialylated glycan patterns through bivalent antibody-lectin architecture Limited off-tumor reactivity observed due to weak baseline affinity of the lectin domain in preclinical studies
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a mechanistic and preclinical review proposing a novel therapeutic concept without clinical trial data, focusing on laboratory evidence and theoretical rationale.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Tumor immune evasion remains one of the most persistent obstacles in cancer therapy. A key driver is aberrant glycosylation, a near-universal feature of malignant transformation that reshapes the tumor surface into a dense, immunosuppressive glycan shield. Hypersialylation, truncated O-glycans, and other tumor-associated carbohydrate antigens engage inhibitory receptors such as Siglec-7 and Siglec-9 on natural killer cells and macrophages, silencing innate immune surveillance. These glycan alterations also stabilize immune checkpoints, including PD-L1, and shield tumor antigens like HER2 and MUC1 from antibody recognition, limiting the effectiveness of conventional immunotherapies. Antibody-lectin chimeras (AbLecs) offer a structurally elegant solution. By fusing a tumor-targeting antibody, such as a HER2-directed IgG1, with a lectin-Fc decoy domain, AbLecs achieve dual recognition of protein antigens and hypersialylated glycan patterns simultaneously. This bivalently structured architecture increases avidity, physically excludes inhibitory Siglec receptors from the immunological synapse, and restores antibody-dependent cellular cytotoxicity and phagocytosis. Preclinical studies show that HER2-directed AbLecs outperform trastuzumab in reducing tumor burden and lung metastases in humanized Siglec mouse models, with limited off-tumor reactivity due to the weak baseline affinity of the lectin domain. This review covers tumor glycobiology, lectin biology, AbLec engineering, and antitumor mechanisms. Key challenges, including glycan heterogeneity, manufacturing complexity, and off-tumor toxicity, are discussed alongside glycomic biomarker strategies and combination regimens. AbLecs represent a meaningful advance in glyco-immunotherapy, turning the tumor glycocalyx from a protective shield into a viable therapeutic target.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.